secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPT Therapeutics, Inc. (—)
CIK:        0001673772
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001193125-26-086878
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GSK completes acquisition of RAPT Therapeutics for $58.00 per share; RAPT to be delisted
--------------------------------------------------------------------------------

- Offer price of $58.00 per share; approx. 93.36% of outstanding shares validly tendered.
- Merger completed March 3, 2026 under DGCL Section 251(h); RAPT now a wholly owned GSK subsidiary.
- Shares delisted from Nasdaq; Form 25 and Form 15 to be filed to deregister and suspend SEC reporting.
- Board replaced: all prior directors resigned; Kevin Ryan and Justin Huang appointed as directors; new officers named.
- Outstanding equity awards converted to cash consideration per Merger Agreement terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1673772/000119312526086878/0001193125-26-086878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1673772/000119312526086878/d69681d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-086878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer